%0 Journal Article
%T Safety and efficacy of cryoablation of Soft-Tissue tumors.
%A Bodard S
%A Marcelin C
%A Kastler A
%A Dimopoulos PM
%A Petre EN
%A Frandon J
%A Razakamanantsoa L
%A Cornelis FH
%J Br J Radiol
%V 0
%N 0
%D 2024 Apr 8
%M 38588564
%F 3.629
%R 10.1093/bjr/tqae075
%X OBJECTIVE: To assess the safety and efficacy of percutaneous cryoablation (CA) of soft-tissue tumors (desmoid tumors (DT), vascular malformations (VM), and abdominal wall endometriosis (AWE)).
METHODS: This systematic review of studies published before January 2024 encompassed a detailed analysis of CA techniques and technical aspects for the treatment of soft-tissue tumors. Data concerning CA efficacy, complication rates, and other relevant metrics was extracted and included for analysis.
RESULTS: The analysis included 27 studies totaling 554 CA procedures. For DT (13 studies, 393 sessions), CA showed an average pain reduction of 79 ± 17% (range: 57-100) and a lesion volume decrease of 71.5 ± 9.8% (range: 44-97). VM (4 studies, 58 sessions) had a 100% technical success rate and an average pain reduction of 72 ± 25% (range: 63-85). The average pain reduction for AWE (6 studies, 103 sessions) was 82 ± 13% (range: 62-100). Overall, the complication rate for CA was low, with minor adverse events (AE) in about 20% of patients and major events in less than 5% of patients.
CONCLUSIONS: Showing substantial efficacy in pain reduction and lesion volume decrease, as well as low incidence of severe AE, CA presents as a highly effective and safe alternative for the treatment of soft-tissue tumors.
CONCLUSIONS: CA is effective and safe in treating soft-tissue tumors, particularly DT, VM, and AWE.